(Q37872791)

24 August 2017

1 reference

title

MEK inhibitors: a patent review 2008 - 2010. (English)

1 reference

24 August 2017

John I Trujillo

1

1 reference

24 August 2017

language of work or name

English

0 references

publication date

9 May 2011

1 reference

Expert Opinion on Therapeutic Patents

24 August 2017

published in

1 reference

24 August 2017

volume

21

1 reference

24 August 2017

issue

7

1 reference

24 August 2017

page(s)

1045-1069

1 reference

24 August 2017

cites work

Emerging MEK inhibitors.

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Recent advances of MEK inhibitors and their clinical progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles-O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of RO5068760, an MEK inhibitor, in healthy volunteers: assessment of target suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Preclinical in vivo evaluation of efficacy, pharmacokinetics, and pharmacodynamics of a novel MEK1/2 kinase inhibitor RO5068760 in multiple tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.577068

10.1517/13543776.2011.577068

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference